v3.25.1
Collaborations - Additional Information (Details)
1 Months Ended 12 Months Ended
Oct. 31, 2023
program
Jul. 31, 2018
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue     $ 189,896,000 $ 219,638,000 $ 299,489,000
Cost of revenue     89,892,000 121,739,000 167,204,000
Current liabilities of discontinued operations     0 21,372,000  
Payable for shared costs included in liabilities subject to compromise     113,504,000 0  
Discontinued Operations          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Research and development     31,611,000 96,037,000 100,962,000
Current liabilities of discontinued operations     0 21,372,000  
GSK          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Collaboration agreement, period   4 years      
GSK | Related Party          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue     0 11,800,000 47,400,000
Cost of revenue     0 300,000 500,000
Payable for shared costs included in liabilities subject to compromise     2,300,000 10,600,000  
GSK | Related Party | Discontinued Operations          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Research and development     500,000 12,800,000 10,700,000
GSK 2023 Amendment          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from license fees       20,000,000.0  
License for data access expiration period 1 year        
Programs, opted-out of cost sharing and other research and development | program 3        
GSK 2023 Amendment | Related Party          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue for customer services     300,000 20,000,000.0  
Revenue     $ 19,700,000 $ 0 $ 0